AstraZeneca

AstraZeneca is a holding company. Through its subsidiaries, Co. operates as a biopharmaceutical company engaged in discovering, developing, manufacturing and commercializing its pipeline of small molecule and biologic prescription medicines, including targeted business development through collaboration, in-licensing and acquisitions. Co. is focused on three main therapy areas: Oncology, Cardiovascular and Metabolic Diseases, and Respiratory. Co. is also selectively active in autoimmunity, infection and neuroscience. In addition, Co. works across small molecules, oligonucleotides and other drug platforms, as well as biologic medicines.
  • TickerAZN
  • ISINGB0009895292
  • ExchangeLondon Stock Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited Kingdom

Analysts

Ahmed Ben Salem ...
  • Alfred Glaser
  • Anis Zgaya
  • Antoine Boivin-Champeaux
  • Benoit Valleaux
  • Charles Lepetitpas
  • Delphine Brault
  • Emmanuel Matot
  • Florent Laroche-Joubert
  • Haris Ladouari
  • Jerôme Bodin
  • Laurence Hofmann
  • Louis Boujard, CFA
  • Marc Lavaud
  • Martial Descoutures
  • Nicolas David
  • Oussema Denguir
  • Philippe Ourpatian
  • Pierre Tegner
  • Stephane Houri
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 02/14/2020

...

Martial Descoutures ...
  • Oussema Denguir

AstraZeneca : Health scare in China prompts cautious guidance

>Disappointing year-end in sales and margin - AstraZeneca has just published its Q4 2019 results, which were disappointing both in terms of sales and margin. Despite continued strong growth momentum (sales up 9% cc in the quarter), recent launches have performed less well than expected. Tagrisso undershot expectations by -4%, Lynparza -2% vs consensus and Imfinzi -7% vs the consensus. This disappointment is offset by the strong performance of Symbicort (attractive ba...

Eric Le Berrigaud

ASTRAZENECA: 2020 will show a clear leverage | BUY - TOP PICKS | 8350p(+9%)

ASTRAZENECA - BUY - TOP PICKS | 8350p(+9%) 2020 will show a clear leverage AZ hits the bottom-end of the core EPS guidance in 2019 Guidance for 2020 is at the low-end of expectations The guidance reflects the start of the growth phase

Ahmed Ben Salem ...
  • Alfred Glaser
  • Anis Zgaya
  • Antoine Boivin-Champeaux
  • Benoit Valleaux
  • Charles Lepetitpas
  • Delphine Brault
  • Emmanuel Matot
  • Florent Laroche-Joubert
  • Haris Ladouari
  • Jerôme Bodin
  • Laurence Hofmann
  • Louis Boujard, CFA
  • Marc Lavaud
  • Martial Descoutures
  • Nicolas David
  • Oussema Denguir
  • Philippe Ourpatian
  • Pierre Tegner
  • Stephane Houri
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 14/02/2020

...

Martial Descoutures ...
  • Oussema Denguir

AstraZeneca : La Chine conduit à une guidance prudente

>Une fin d’année décevante au niveau des ventes t de la marge - AstraZeneca vient de publier ses résultats du T4 2019 qui s’avèrent décevants que ce soit au niveau des ventes et de la marge. Malgré une dynamique de croissance toujours solide (hausse de 9% à tcc sur ses ventes lors de ce trimestre), les derniers lancements ont fait moins bien qu’attendu. En effet, Tagrisso sort -4% en dessous des attentes, Lynparza -2% vs Cs et Imfinzi -7% vs Cs. Cette déception est co...

AstraZeneca PLC - September 2019 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Moody's: China's rising demand for drugs will fuel foreign pharma companies' growth into 2023 (Simplified Chinese translation)

企业融资部 Moody's France SAS96 Boulevard Haussmann Paris, 75008 France 联系电话. Moody's France SAS 96 Boulevard Haussmann Paris, 75008 France 联系电话. *请注意新闻稿之英文原版已于巴黎时间 9 月 24 日发放.

Moody's: China's rising demand for drugs will fuel foreign pharma companies' growth into 2023

Announcement: Moody's: China's rising demand for drugs will fuel foreign pharma companies' growth into 2023. Global Credit Research- 24 Sep 2019. -Relaxed regulation, improving healthcare coverage to drive China's pharmaceutical demand.

Moody's announces completion of a periodic review of ratings of AstraZeneca PLC

Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of AstraZeneca PLC. Global Credit Research- 24 Sep 2019. Paris, September 24, 2019-- Moody's Investors Service has completed a periodic review of the ratings of AstraZeneca PLC and other ratings that are associated with the same analytical unit.

Moody's: China's rising demand for drugs will fuel foreign pharma companies' growth into 2023

Announcement: Moody's: China's rising demand for drugs will fuel foreign pharma companies' growth into 2023. Global Credit Research- 24 Sep 2019. -Relaxed regulation, improving healthcare coverage to drive China's pharmaceutical demand.

Martial Descoutures ...
  • Oussema Denguir

AstraZeneca : Health scare in China prompts cautious guidance

>Disappointing year-end in sales and margin - AstraZeneca has just published its Q4 2019 results, which were disappointing both in terms of sales and margin. Despite continued strong growth momentum (sales up 9% cc in the quarter), recent launches have performed less well than expected. Tagrisso undershot expectations by -4%, Lynparza -2% vs consensus and Imfinzi -7% vs the consensus. This disappointment is offset by the strong performance of Symbicort (attractive ba...

Eric Le Berrigaud

ASTRAZENECA: 2020 will show a clear leverage | BUY - TOP PICKS | 8350p(+9%)

ASTRAZENECA - BUY - TOP PICKS | 8350p(+9%) 2020 will show a clear leverage AZ hits the bottom-end of the core EPS guidance in 2019 Guidance for 2020 is at the low-end of expectations The guidance reflects the start of the growth phase

Martial Descoutures ...
  • Oussema Denguir

AstraZeneca : La Chine conduit à une guidance prudente

>Une fin d’année décevante au niveau des ventes t de la marge - AstraZeneca vient de publier ses résultats du T4 2019 qui s’avèrent décevants que ce soit au niveau des ventes et de la marge. Malgré une dynamique de croissance toujours solide (hausse de 9% à tcc sur ses ventes lors de ce trimestre), les derniers lancements ont fait moins bien qu’attendu. En effet, Tagrisso sort -4% en dessous des attentes, Lynparza -2% vs Cs et Imfinzi -7% vs Cs. Cette déception est co...

Eric Le Berrigaud

ASTRAZENECA: Enhertu and Brilinta meet two trial endpoints | BUY - TOP PICKS | 8350p(+9%)

ASTRAZENECA - BUY - TOP PICKS | 8350p(+9%) Enhertu and Brilinta meet two trial endpoints Enhertu meets primary endpoint in DESTINY-Gastric01 Brilinta meets primary endpoint in THALES Divestment of anti-hypertensive drugs for USD350m Unchanged FV

Eric Le Berrigaud

ASTRAZENECA | BUY | 8350p vs. 7950p Two more approvals for AZ in the US before the New Year

ASTRAZENECA | BUY | 8350p vs. 7950p Two more approvals for AZ in the US before the New Year Enhertu approved in a record time Strong validation of data for Enhertu Not yet a major impact on valuation A new FV of GBp8,350, supportive of a BUY rating

1 director bought

A director at AstraZeneca bought 8,500 shares at 5,800p and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board memb...

Ahmed Ben Salem ...
  • Alfred Glaser
  • Anis Zgaya
  • Antoine Boivin-Champeaux
  • Benoit Valleaux
  • Charles Lepetitpas
  • Delphine Brault
  • Emmanuel Matot
  • Florent Laroche-Joubert
  • Haris Ladouari
  • Jerôme Bodin
  • Laurence Hofmann
  • Louis Boujard, CFA
  • Marc Lavaud
  • Martial Descoutures
  • Nicolas David
  • Oussema Denguir
  • Philippe Ourpatian
  • Pierre Tegner
  • Stephane Houri
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 02/14/2020

...

Ahmed Ben Salem ...
  • Alfred Glaser
  • Anis Zgaya
  • Antoine Boivin-Champeaux
  • Benoit Valleaux
  • Charles Lepetitpas
  • Delphine Brault
  • Emmanuel Matot
  • Florent Laroche-Joubert
  • Haris Ladouari
  • Jerôme Bodin
  • Laurence Hofmann
  • Louis Boujard, CFA
  • Marc Lavaud
  • Martial Descoutures
  • Nicolas David
  • Oussema Denguir
  • Philippe Ourpatian
  • Pierre Tegner
  • Stephane Houri
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 14/02/2020

...

Ahmed Ben Salem ...
  • Alain William
  • Antoine Boivin-Champeaux
  • Charles Lepetitpas
  • Emira Sagaama
  • Emmanuel Matot
  • Johanna Jourdain
  • Louis Boujard, CFA
  • Martial Descoutures
  • Matthias Desmarais
  • Nicolas David
  • Oussema Denguir
  • Philippe Ourpatian
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 12/17/2019

...

Charles Lepetitpas ...
  • Emira Sagaama
  • Emmanuel Matot
  • Louis Boujard, CFA
  • Martial Descoutures
  • Nicolas David
  • Oussema Denguir
  • Philippe Ourpatian

ODDO BHF Small & MIDCAP MORNING NEWS - 17/12/2019

...

Charles Lepetitpas ...
  • Emira Sagaama
  • Emmanuel Matot
  • Louis Boujard, CFA
  • Martial Descoutures
  • Nicolas David
  • Oussema Denguir
  • Philippe Ourpatian

ODDO BHF Small & MIDCAP MORNING NEWS - 12/17/2019

...

ASTRAZENECA PLC. loses on its star level and is downgraded to Slightly Positive

The independent financial analyst theScreener just slightly lowered the general evaluation of ASTRAZENECA PLC. (GB), active in the Pharmaceuticals industry. The title has lost a star(s) at the fundamental level and now shows 1 out of 4 stars. Its exposure to market risk remains nonetheless the same and can be still described as defensive. theScreener slightly downgrades the general evaluation to Slightly Positive for the title on account of the lost star(s). As of the analysis date January 31, 2020, the closing price was GBp 7,424.00 and its potential was estimated at GBp 8,460.42.

Nurhayati Wan

AstraZeneca PLC

Nurhayati Wan

AstraZeneca

Nurhayati Wan

AstraZeneca

Nurhayati Wan

AstraZeneca

Tougher Sledding: Stocks Reach First Major Hurdles (GMR Weekly Notes -21 Jan 2019)

Markets This Week: Stocks: ConocoPhillips (COP); Apple (AAPL); AbbVie (ABBV); Nokia (NOK); AstraZeneca (AZN); Aurora Cannabis (ACB); General Electric (GE) Forex: EURCHF; USDRUB; AUDNZD Rates: EDZ9; 2s/10s; Bunds (GDBR10)

The 'Trap-Door'' and Other Formations; Stocks Point Lower Into Dec (GMR Weekly Notes - 26 Nov 2018)

Markets This Week: Stocks: S&P500 (SPX); DJIA (INDU); Financial Sector ETF (XLF); Goldman Sachs (GS); Dish Network (DISH); Palo Alto Networks (PANW); Microsoft (MSFT); AstraZeneca (AZN) Forex: Dollar Index (DXY); USDCNH; USDBRL Rates: 2s/5s/10s Fly (BF0205010); 5s/30s

GMR Weekly Notes - Week of 21 May 2018

Markets This Week: Stocks: Nvidia (NVDA); JD.com (JD); Charter Comm (CHTR); Facebook (FB); XLP; AstraZeneca (AZN) Rates: Gilts (GUKG10); US 10s/30s; EDZ9 FX: USDMXN; USDINT; USDZAR

Bruno de La Rochebrochard ...
  • Eric Le Berrigaud
  • Jean-Jacques Le Fur
  • Victor Floc’h

Healthcare Top Picks Q1 2020 Healthcare: Astrazeneca, Genfit, Korian, Roche

Healthcare Top Picks Q1 2020 Healthcare: Astrazeneca, Genfit, Korian, Roche Looking back to Q4 2019 and 2019 as a whole What is ahead of us in Q1 2020

MarketLine Department

Calithera Biosciences, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances And Investments

Summary Marketline's Calithera Biosciences, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Calithera Biosciences, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its compet...

Eric Le Berrigaud

SECTOR | Pharmaceuticals | BG OncoDay 2019: clear upside in early-stage NSCLC

SECTOR | Pharmaceuticals | BG OncoDay 2019: clear upside in early-stage NSCLC At our Annual Oncology Day this year, two KOLs (i) summarized the key learnings from ASCO 2019 and (ii) focused specifically on the advances in lung cancer. Then, out of the five companies presenting, three did so in plenary sessions, and we report here the main messages they conveyed

MarketLine Department

Novo Nordisk A/S - Strategy, SWOT and Corporate Finance Report

Summary Novo Nordisk A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Novo Nordisk AS (Novo Nordisk or 'the company') is a pharmaceutical company that manufactures and develops biological medicines primarily focused on diabetes including both Type 1 and Type 2. Other therapy areas covered by the company include obesity, Atherosclerosis, Non-alcoholic steatoh...

MarketLine Department

H. Lundbeck A/S - Strategy, SWOT and Corporate Finance Report

H. Lundbeck A/S - Strategy, SWOT and Corporate Finance Report Summary H. Lundbeck A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights H. Lundbeck A/S (Lundbeck or 'the company') is a specialty pharmaceutical company primarily focusing on brain diseases. The company’s products are focused on treating depression/anxiety, Alzheimer’s disease, schizophrenia, alcoho...

Expert Corporate Governance Service (ECGS)

AstraZeneca - AGM 26 April 2019

Item 2: Declare a Dividend  The proposed dividend is the same as that of the previous fiscal year. It has remained unchanged at $2.80 per share since 2015.  The Board maintains a progressive dividend policy and has the intention to maintain or grow the dividend each year with the aim of striking a balance between the interest of the business, financial creditors and shareholders. However, in the current year the dividend is not covered by earnings or free cash flow.  In fact, free cash flow has not been able to cover the dividend for five years in a row.  We recommend shareholders oppose.  I...

Astrazeneca PLC – Proxinvest Corporate Governance Rating ® : C

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

Dave Nicoski ...
  • Ross LaDuke

Global Equity Strategy

Global equities (MSCI ACWI) are testing 52-week lows as prices have been consolidating over the last 1-2 months. Investors' primary sources of angst continue to revolve around concerns of (1) the global shift toward tighter monetary policy and the potential for perceived policy missteps, (2) trade and tariffs, and (3) the potential negative effects both (1) and (2) may have on global growth. Comments from Fed Chair Powell that interest rates are “just below” the neutral rate and the 90-day tariff ceasefire agreement between the U.S. and China have not been able to calm the markets. In Europe, ...

Jérôme VINERIER

Analyse court terme - ASTRAZENECA : La tendance de fond est clairement orientée à la hausse.

La tendance de fond est clairement orientée à la hausse. Le MACD est positif, il confirme cette tendance. Le mouvement peut se poursuivre. Les objectifs suivants sont à 6 145,00 p et 6 502,00 p. La tendance serait invalidée sous le support à 5 100,00 p.

Jérôme VINERIER

Short term view - ASTRAZENECA : The background trend is clearly bullish.

The background trend is clearly bullish. The MACD is positive, it confirms that trend. The movement can go on. The following targets are at 6,145.00 p and 6,502.00 p. The trend would be invalidated below the support at 5,100.00 p.

Jérôme VINERIER

Analyse court terme - ASTRAZENECA : Les cours progressent encore.

La tendance de fond est clairement orientée à la hausse. Les cours progressent encore, mais le mouvement montre moins de puissance. La prochaine résistance est à 6 145,00 p. La rupture du support à 5 100,00 p invaliderait cette tendance.

Jérôme VINERIER

Short term view - ASTRAZENECA : Prices are still making progress

The background trend is clearly bullish. Prices are still making progress but there is less power in the movement. The next resistance is at 6,145.00 p. Breaking below the support at 5,100.00 p would invalidate the trend.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch